End-stage renal disease

End-stage renal disease is the advanced stage of kidney failure in which dialysis or kidney transplantation becomes necessary to sustain life. Its importance in this literature extends beyond loss of renal function: patients with End-stage renal disease are especially vulnerable to hepatitis C virus infection, its extrahepatic complications, and the competing risks created by dialysis, antiviral toxicity, transplantation, immunosuppression, and graft loss.

Definition and Clinical Setting

End-stage renal disease appears in the book primarily as the clinical state requiring long-term dialysis or consideration of kidney transplantation. Chronic hepatitis C is particularly consequential in this setting because it affects both survival and the feasibility of treatment. After acute infection, HCV becomes chronic in approximately 80% of patients and progresses to cirrhosis in about 20% after 20 years. Among patients with End-stage renal disease and chronic HCV infection, interferon-based treatment has historically produced cure rates of approximately 30–45%, while the addition of ribavirin, although beneficial in the general population, is difficult in dialysis patients because of poor tolerance.

The burden is not confined to the liver. HCV is presented as a systemic disease capable of producing autoimmune, dermatological, and renal disease, including mixed cryoglobulinemia and cryoglobulinemic glomerulonephritis. This systemic framing led Kidney Disease Improving Global Outcomes to treat HCV as a major nephrology, dialysis, and transplantation topic and to produce a comprehensive clinical practice guideline for prevention, diagnosis, evaluation, and treatment in chronic kidney disease.

Diagnosis and Disease Assessment

HCV status in End-stage renal disease must be separated into antibody evidence, active viremia, and the consequences of established disease. Diagnosis of infection begins with anti-HCV antibodies detected by third-generation enzyme-linked immunoassays, but antibodies alone cannot distinguish resolved infection from chronic infection. Active chronic infection requires both anti-HCV positivity and detectable HCV RNA, with molecular assays sensitive to approximately 15 IU/ml; chronicity is defined by persistent HCV RNA for more than six months.

Assessment does not end with confirming viremia. Active chronic infection requires evaluation of hepatic and extrahepatic effects, including cryoglobulinemia-associated vasculitis. Liver injury may be assessed by liver biopsy or noninvasive methods such as FibroTest, FibroMeter, HepaScore, the Forns index, Fib-4, and FibroScan elastometry. Agreement among biochemical and morphological tests can avoid roughly half of liver biopsies and permits yearly fibrosis monitoring in untreated patients.

The same caution applies when a patient with End-stage renal disease is being considered for kidney transplantation. Up to 25% of candidates with active HCV infection have advanced liver fibrosis on biopsy despite well-compensated disease and no obvious clinical suspicion. In regions with low HCV prevalence, recommended screening begins with an enzyme immunoassay followed by nucleic acid testing when antibodies are detected. In high-prevalence settings, nucleic acid testing should be the initial test because a negative antibody assay cannot reliably exclude infection.

Dialysis, Transmission, and Patient Burden

Patients with End-stage renal disease receiving hemodialysis were recognized as a high-risk group soon after reliable HCV serology became available. During the early 1990s, high prevalence reflected both transfusion exposure and continuing nosocomial transmission within dialysis units. HCV prevalence correlated with time on dialysis independently of transfusion burden, was higher in hemodialysis than in peritoneal or home dialysis, and remained substantial among patients who had never received transfusions.

The transfusion contribution fell sharply with improved blood-donor screening and widespread use of erythropoiesis-stimulating agents. The estimated risk of post-transfusion hepatitis C declined from approximately 0.5% per blood unit in the 1980s to about 0.0001%, or one case per million blood units, in the United States. As transfusion safety improved, infection-control practices and the possibility of transmission within dialysis units became increasingly important. Despite protective measures and universal screening of blood products, patients on dialysis continued to face an increased risk of acquiring HCV.

HCV-related liver disease is often clinically silent in long-term dialysis. Fatigue, asthenia, and cognitive impairment are difficult to attribute because they are common in dialysis patients regardless of serologic status. Biochemical abnormalities may nevertheless appear: transaminase and gamma-glutamyl transpeptidase levels can be elevated, anti-HCV seropositivity has been independently associated with alkaline phosphatase activity, and HCV-infected patients have shown higher intact parathormone levels, approximately 422 versus 338 pg/ml in one comparison. Cirrhosis remains relatively uncommon among dialysis patients in the Western world, occurring in approximately 1.5–2% in some registries.

The consequences also reach cardiovascular health and quality of life. In a prospective study of 94 dialysis patients, HCV viremia was independently associated with high aortic pulse-wave velocity, with an odds ratio of 9.7, and HCV RNA-positive patients had significantly different cerebrovascular- and cardiovascular-event-free survival curves. The proposed mechanism involved an atherogenic contribution through worsening metabolic syndrome and dyslipidemia, although a meta-analysis of observational studies did not find a significant unadjusted association between HCV and cardiovascular mortality. In another study of 165 patients receiving regular dialysis, 83 anti-HCV-positive patients had a significantly lower mental component score on the SF-36 quality-of-life measure, while no association was observed with the physical component score. Depression, fatigue, cognitive impairment, and the psychological burden of diagnosis may therefore form part of the HCV experience in End-stage renal disease even when liver disease is not overt.

Antiviral Treatment and Its Constraints

The rationale for treating HCV in End-stage renal disease rests on more than viral eradication. HCV is associated with increased overall and liver-related mortality in dialysis patients, liver disease may progress more rapidly after kidney transplantation, and interferon given after transplantation increases the risk of rejection and graft loss. For these reasons, antiviral therapy should be individualized in dialysis patients, while all HCV-positive kidney-transplant candidates should be assessed for treatment before transplantation.

Historically, standard interferon-alpha or pegylated interferon, alone or with ribavirin, formed the available treatment options. In acute HCV infection among dialysis patients, interferon-based treatment achieved response rates above 80%. In chronic infection, approximately one third of dialysis patients treated with interferon monotherapy achieved a sustained virologic response, with no clear difference between conventional and pegylated interferon. The dropout rate was high, however, because of adverse effects.

Treatment duration and response depend on viral genotype and early viral kinetics. In the general population, pegylated interferon combined with ribavirin produced sustained virologic response rates of roughly 80% for genotypes 2 and 3 and 40–50% for genotypes 1 and 4. Genotypes 1 and 4 were generally treated for 48 weeks, whereas genotypes 2 and 3 were treated for 24 weeks. A rapid response by week 12, defined by undetectable HCV RNA or at least a two-log decrease, predicted treatment success. Male sex, older age, higher body mass index, coinfection, insulin resistance, and advanced liver disease were associated with poorer response.

Toxicity narrows the therapeutic margin in End-stage renal disease. Interferon treatment can cause flu-like symptoms, fever, fatigue, headache, myalgia, arthralgia, anemia, neutropenia, depression, and anxiety. These effects reduce quality of life, lead to dose reduction in approximately 35–42% of patients, and result in discontinuation in about 30%. Ribavirin is especially difficult to tolerate in dialysis patients, which explains why the improved sustained virologic response seen with combination therapy in the general population cannot simply be transferred to this group.

The therapeutic landscape was nevertheless beginning to change. Direct-acting antiviral drugs were developed against viral enzymes, including genotype 1-specific NS3/NS4A protease and NS5B polymerase targets, as well as broader-spectrum NS5A and entry targets. First-generation protease inhibitors, telaprevir and boceprevir, increased sustained virologic response rates in genotype 1 infection by approximately 20–30%, but their safety, cost, adherence requirements, resistance, and drug interactions remained important limitations.

Transplantation and Renal Complications

Kidney transplantation changes the balance of risks rather than removing the consequences of End-stage renal disease with HCV. Candidates with chronic HCV infection may have a longer life expectancy after transplantation than while remaining on dialysis, making pretransplant antiviral treatment attractive. At the same time, immunosuppressive therapy can accelerate liver disease, and interferon cannot safely be relied upon after transplantation because of its association with rejection and graft loss.

HCV is an independent risk factor for renal allograft loss, including in protocol-biopsy studies. Some of this effect may reflect the higher immunologic risk of the HCV-infected transplant population, which often includes retransplantation, prolonged renal disease, and heightened cellular and humoral immune responses. HCV has been associated with glomerulitis and transplant glomerulopathy, lesions linked to anti-HLA antibodies and antibody-mediated rejection. Thrombotic microangiopathy related to pretransplant anticardiolipin antibodies has also been described, although it is uncommon among HCV-infected transplant recipients.

HCV-infected renal allograft recipients are prone to immune-complex-mediated glomerulonephritis, as are nontransplanted patients. HCV was identified as a major risk factor for post-transplant proteinuria, and de novo membranoproliferative glomerulonephritis was reported in HCV-infected renal allograft recipients. Later observations connected this lesion with type II mixed cryoglobulinemia involving IgM-kappa monoclonal components. Unlike HCV-related membranoproliferative glomerulonephritis outside transplantation, renal allograft cases usually have very low cryocrit levels, often below 5%, which can make cryoglobulins difficult to detect and characterize. HCV RNA may be much more concentrated in the cryocrit than in serum, supporting a pathogenic role for the virus and possible activation of the classical complement pathway.

The clinical picture of post-transplant membranoproliferative glomerulonephritis includes hypertension, microscopic hematuria, proteinuria, renal dysfunction, and sometimes nephrotic syndrome. Biopsy may show chronic injury, focal or diffuse mesangial proliferation, double contours, and parietal IgM and C3 deposits. Electron microscopy can be required to distinguish membranoproliferative glomerulonephritis from transplant glomerulopathy: the former shows subendothelial electron-dense deposits, whereas the latter shows radiolucent areas in the glomerular basement membrane. The two lesions can coexist, illustrating how humoral immunity and HCV-associated autoimmunity may act together to worsen allograft outcome.

Membranous glomerulonephritis has also been associated with HCV in renal allografts and usually presents with nephrotic syndrome. Its mechanism is less clear because cryoglobulins, immune complexes, and complement activation are generally absent. This uncertainty reinforces the broader point that End-stage renal disease is not a single disease state but a setting in which infection, renal pathology, immunology, treatment toxicity, and transplantation outcomes intersect.

Broader Significance

The HCV experience of End-stage renal disease is organized around a sequence of narrowing choices: infection must be identified despite asymptomatic disease; active viremia must be separated from resolved antibody positivity; liver and extrahepatic injury must be staged; treatment must be weighed against anemia, neuropsychiatric effects, and poor tolerance; and transplantation must be considered alongside the risks of immunosuppression and graft failure. The result is a clinical state in which kidney failure amplifies the consequences of a systemic viral infection while simultaneously limiting the therapies available to control it.

Its significance is therefore both biological and institutional. End-stage renal disease exposes patients to repeated procedures and transfusion histories, makes dialysis units potential sites of infection control failure, places HCV-positive candidates under intensive screening before transplantation, and turns viral status into a determinant of treatment timing and graft prognosis. The evidence also preserves uncertainty: observational data do not establish every proposed cardiovascular or immunologic pathway, and some renal lesions associated with HCV remain mechanistically unresolved. Even so, the consistent pattern is clear—HCV in End-stage renal disease is not an incidental laboratory finding but a factor that reshapes survival, quality of life, antiviral decisions, and the future of the transplanted kidney.